Last updated: 06/13/2019 12:12:51
Completed clinical study under GSK sponsorship. The product that is studied in this clinical study, together with the rights to the data and results generated, has been transferred by GSK to Pfizer. GSK’s Clinical Study Register is no longer maintained for this study. To request access to clinical study data from Pfizer, go here: http://www.pfizer.com/research/clinical_trials/trial_data_and_results

Immunogenicity and safety study of GSK Biologicals' meningococcal conjugate vaccine when co-administered with routine vaccines in healthy infants and toddlers

GSK study ID
114858
See study documents
Clinicaltrials.gov ID
NCT01340898
See results summary
EudraCT ID
2013-002537-37
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Immunogenicity and safety study of GSK Biologicals' meningococcal conjugate vaccine (GSK 134612) when co-administered with routine vaccines in healthy infants and toddlers
Trial description: This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK 134612 in healthy infants, when co-administered with other infant vaccines, on three different dose schedules.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:

Number of subjects with serum bactericidal assay using rabbit complement (rSBA) against Neisseria meningitidis serogroups antibody titers greater than or equal to (≥) 1:8, one month post dose 3 for the Nimenrix 3+1 Group

Timeframe: At Month 5 (one month post-dose 3)

Secondary outcomes:

Number of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY antibody titers greater than or equal to (≥) 1:8 prior to and one month after the booster dose for the Nimenrix 3+1 Group

Timeframe: At Month 13 (prior booster) and at Month 14 (one month after the booster dose)

Number of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY antibody titers greater than or equal to (≥) 1:128, one month post-dose 3, prior to and one month after the booster dose for the Nimenrix 3+1 Group

Timeframe: At Months 5 (one month post-dose 3), 13 (prior booster-dose) and 14 (one month after the booster dose)

rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY antibody titers one month post dose 3, prior to and one month after the booster dose for the Nimenrix 3+1 Group

Timeframe: At Months 5 (one month post-dose 3), 13 (prior booster-dose) and 14 (one month after the booster dose)

Number of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY antibody titers greater than or equal to (≥) the cut-off values for the Nimenrix 1+1 and Nimenrix Control Groups

Timeframe: At Months 5 (one month post-primary dose for Nimenrix 1+1 Group), 13 (prior booster dose for Nimenrix 1+1 and prior primary dose for Nimenrix Control Group) and 14 (post booster dose for Nimenrix 1+1 and post-primary dose for Nimenrix Control Group)

rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY antibody titers for Nimenrix 1+1 and Nimenrix Control Groups

Timeframe: At Months 5 (one month post-primary dose for Nimenrix 1+1 Group), 13 (prior booster dose for Nimenrix 1+1 and prior primary dose for Nimenrix Control Group) and 14 (post booster dose Nimenrix 1+1 and post-primary dose for Nimenrix Control Group)

Number of subjects with booster responses for rSBA-MenA, C rSBA-MenC, Y rSBA-MenY and W-135 rSBA-MenW-135 in Nimenrix 3+1 and Nimenrix 1+1 groups and with vaccine response in Nimenrix Control Group

Timeframe: At Month 14 (one month post-booster dose for Nimenrix 3+1 and Nimenrix 1+1 and post-primary dose for Nimenrix Control Group)

Number of subjects with serum bactericidal assay using human complement against Neisseria meningitidis serogroups A, C, W-135, Y antibody titers greater than or equal to (≥) the cut-off values (one month post-primary for Nimenrix 3+1 and 1+1 Groups)

Timeframe: At Month 5 (one month post-primary for Nimenrix 3+1 and Nimenrix 1+1 Groups)

hSBA-MenA, hSBA-MenC, hSBA-MenW-135, and hSBA-Men-Y antibody titers (one month post-primary for Nimenrix 3+1 and Nimenrix 1+1 Groups)) -randomized subset of 50% of subjects of all three groups

Timeframe: At Month 5 (one month post-primary for Nimenrix 3+1 and Nimenrix 1+1 Groups)

Number of participants with hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-Men-Y titers (≥) the cut-off value (pre- and post-booster for Nimenrix 3+1 and 1+1 Groups and pre- and post-vaccination for Nimenrix Control)

Timeframe: At Month 13 (pre-booster for Nimenrix 3+1 and Nimenrix 1+1 Groups and pre-vaccination for Nimenrix Control), and at Month 14 (post-booster for Nimenrix 3+1 and Nimenrix 1+1 Groups and post-vaccination for Nimenrix Control)

hSBA-MenA, hSBA-MenC, hSBA-MenW-135, and hSBA-Men-Y antibody titers (pre-booster for Nimenrix 3+1 and 1+1 Groups and pre-vaccination for Nimenrix Control, and post-booster for Nimenrix 3+1 and 1+1 Groups and post-vaccination for Nimenrix Control)

Timeframe: At Month 13 (pre-booster for Nimenrix 3+1 and Nimenrix 1+1 Groups and pre-vaccination for Nimenrix Control), and at Month 14 (post-booster for Nimenrix 3+1 and Nimenrix 1+1 Groups and post-vaccination for Nimenrix Control)

Number of subjects with booster responses for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY in Nimenrix 3+1 and Nimenrix 1+1 groups and with vaccine response in Nimenrix Control Group

Timeframe: At Month 14 (one month after the booster dose in Nimenrix 3+1 and Nimenrix 1+1 and post-vaccination in Nimenrix Control Group)

Number of subjects with anti-pneumococcal antibody concentrations greater than or equal to (≥) 0.15 micrograms per milliliter (µg/mL).

Timeframe: At Months 5 (one month post-dose 3), Month 13 (prior booster dose) and Month 14 (one month after the booster dose)

Number of subjects with anti-pneumococcal antibody concentrations greater than or equal to (≥) 0.35 micrograms per milliliter (µg/mL)

Timeframe: At Months 5 (one month post-dose 3), Month 13 (prior booster dose) and Month 14 (one month after the booster dose)

Anti-pneumococcal antibody concentrations

Timeframe: At Months 5 (one month post-dose 3), Month 13 (prior booster-dose) and Month 14 (one month after the booster dose)

Number of subjects with anti-diphtheria (anti-D) antibodies

Timeframe: At Month 5 (one month post-dose 3)

Concentration of antibodies against diphtheria antigens (anti-D)

Timeframe: At Month 5 (one month post-dose 3)

Concentration of antibodies against diphtheria antigens (anti-D)

Timeframe: At Month 5 (one month post-dose 3)

Concentration of antibodies against pertussis toxoid (anti-PT), filamentous haemagglutinin (anti-FHA), pertactin (anti-PRN) antigens

Timeframe: At Month 5 (one month post-dose 3)

Number of subjects with anti-pertussis toxoid (anti-PT), anti-filamentous haemagglutinin (anti-FHA), anti-pertactin (anti-PRN) Immunoglobulin G (IgG) antibodies

Timeframe: At Month 5 (one month post-dose 3)

Concentration of antibodies against pertussis toxoid (anti-PT), filamentous haemagglutinin (anti-FHA), pertactin (anti-PRN) antigens

Timeframe: At Month 5 (one month post-dose 3)

Antibody titers for anti-polio type 1, 2 and 3 antibodies

Timeframe: At Month 5 (one month post-dose 3)

Antibody titers for anti-polio type 1, 2 and 3 antibodies

Timeframe: At Month 5 (one month post-dose 3)

Number of subjects with anti-tetanus (anti-T) antibodies

Timeframe: At Months 5 (one month post-dose 3), Month 13 (prior booster-dose) and Month 14 (one month after the booster dose)

Concentration of antibodies against tetanus antigens (anti-T)

Timeframe: At Months 5 (one month post-dose 3), Month 13 (prior booster-dose) and Month 14 (one month after the booster dose)

Number of subjects with anti-tetanus (anti-T) antibodies

Timeframe: At Months 5 (one month post-dose 3), 13 (prior booster-dose) and 14 (one month after the booster dose)

Anti-PRP antibody concentrations (Geometric Mean Concentrations) in a randomized subset of 25% of the subjects

Timeframe: At Month 5 (one month post-dose 3)

Number of subjects with solicited local symptoms (Primary Phase)

Timeframe: Within 8 days (Day 0-7) post primary vaccination

Number of subjects with solicited local symptoms (Booster Phase)

Timeframe: Within 8 days (Day 0-7) post booster vaccination

Number of subjects with solicited general symptoms (Primary Phase)

Timeframe: Within 8 days (Day 0-7) post primary vaccination

Number of subjects with solicited general symptoms (Booster Phase)

Timeframe: Within 8 days (Day 0-7) post booster vaccination

Number of subjects with unsolicited adverse events (AEs) (Primary Phase)

Timeframe: Within 31 days (Day 0-30) post each primary vaccine dose

Number of subjects with unsolicited adverse events (AEs) (Booster phase)

Timeframe: Within 31 days (Day 0-30) post booster vaccination

Number of subjects with new onset of chronic illnesses (NOCIs)

Timeframe: From Day 0 to Month 19

Number of subjects with serious adverse events (SAEs)

Timeframe: From Day 0 to Month 19

Interventions:
  • Biological/vaccine: Meningococcal vaccine GSK 134612
  • Biological/vaccine: SynflorixTM
  • Biological/vaccine: Infanrix-IPV/HiberixTM
    • Enrollment:
    753
    Primary completion date:
    2014-04-08
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Meningococcal Infection
    Product
    GSK134612A
    Collaborators
    Not applicable
    Study date(s)
    January 2012 to October 2015
    Type
    Interventional
    Phase
    3

    Participation criteria

    Sex
    Female & Male
    Age
    6 - 12 weeks
    Accepts healthy volunteers
    Yes
    • Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
    • A male or female, 6 to 12 weeks (42-90 days) of age at the time of the first vaccination.
    • Child in care.
    • Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
    • A male or female, 6 to 12 weeks (42-90 days) of age at the time of the first vaccination.
    • Written informed consent obtained from the parent(s)/LAR(s) of the subject.
    • Healthy subjects as established by medical history and clinical examination before entering into the study.
    • Born after a gestation period of at least 36 weeks.
    Exclusion criteria:
    • Child in care.
    • Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
    • Extended administration of immunosuppressants or other immune-modifying drugs since birth.
    • Planned administration/administration of a vaccine not foreseen by the study protocol during the period 30 days before and after each study vaccine administration, with the exception of rotavirus vaccine and seasonal or pandemic influenza vaccine.
    • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
    • Previous vaccination against diphtheria , tetanus, pertussis, polio (with the exception of a birth dose of OPV), Haemophilus influenzae type b, Streptococcus pneumonia.
    • History of receipt of meningococcal vaccine.
    • Subjects who received a birth dose Hepatitis B vaccines within the 30 days before the administration of the first study vaccine.
    • History of or intercurrent diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b disease, pneumococcal and/or meningococcal disease.
    • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
    • Family history of congenital or hereditary immunodeficiency.
    • History of any reaction or hypersensitivity likely to be exacerbated by any component of th

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Beirut, Lebanon, 1107-2020
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    Durango, Durango, Mexico, 34000
    Status
    Study Complete
    Contact us

    Study documents

    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Results posted on ClinicalTrials.gov

    Recruitment status
    No longer a GSK study
    Actual primary completion date
    2014-04-08
    Actual study completion date
    2015-19-10

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website